Monosaccharide-based nanoparticles are nanoparticles that integrate monosaccharides, such as galactose, on their surface or within their structure, offering a versatile platform for targeted drug delivery and biomedical applications. These nanoparticles are often produced using Various Advanced Techniques, specifically, galactose-modified nanoparticles are frequently produced through galactosylation, thiol–ene reactions, or amide coupling, which allow for precise functionalization of the nanoparticles to enhance targeting and stability.
Fig.1 The schematic diagram of the preparation of GNPs and GAL-PEG-GNPS. (Zhu. et al., 2015)
Our GlycoNano™ Platform offers advanced Glyconanoparticle Development Services and Carbohydrate-based Nanoparticle Production Services. By integrating carbohydrates into nanoparticle structures, our systems are not only biocompatible and biodegradable but also capable of selectively targeting specific cells and tissues.
A key offering under this platform is monosaccharide-based nanoparticle production. This service includes a variety of custom solutions, such as galactose-modified nanoparticles, designed for enhanced targeting and therapeutic efficiency. For example, galactose-modified liposomal nanoparticles, PLGA nanoparticles containing galactose-modified vancomycin, and galactose-modified upconversion nanoparticles. Our service also extends to galactose/chitosan-modified nanoparticles, like galactose-chitosan nanoparticles and galactose-modified 5-fluorouracil nanoparticles, offering tailored solutions for diverse biomedical needs.
| Galactose-modified Nanoparticle Production | |
| Galactosylation-targeted Liposomal Nanoparticles | GSH-responsive PLGA Nanoparticles Containing Galactose-modified Vancomycin |
| ROS-responsive PLGA Nanoparticles Containing Galactose-modified Vancomycin | PLGA Nanoparticles Containing Galactose-modified Vancomycin |
| PLGA Nanoparticles Containing Rapamycin Surface-modified Galactose | Galactose-modified Upconversion Nanoparticles |
| Galactose-mediated Turmeric-Based Bovine Serum Albumin Nanoparticles | Galactose Vinyl Ester Nanoparticles |
| Galactosylated Albumin Magnetic Adriamycin Nanoparticles (Gal-MADM-NP) | Galactose-modified Pea Albumin 1b Nanoparticles |
| Galactose-modified Ricin Nanoparticles | Galactose Conjugated Bean Innocent Protein Nanoparticles |
| Galactose-Myoalbumin Nanoparticle Complex | Galactose Conjugated Wheat Gleysolmin Nanoparticles |
| Galactose-modified Whey Albumin Nanoparticles (Whey Protein-Galactose) | Galactose-modified Rat Serum Albumin Nanoparticles (RSA-Galactose) |
| Galactose-Mouse Serum Albumin Nanoparticle Complex (MSA-Galactose) | Galactose Ova-Galactose Conjugated Ovasmin Nanoparticles (OVA-galactose) |
| Galactose-modified Human Serum Albumin Nanoparticle (HSA-Galactose) | Galactose-modified Bovine Serum Albumin Nanoparticle (BSA-Galactose) |
| Galactose Coupled Tungsten Diselenide Wse2 Nanoparticle (Galactse-Wse2)(Wse2-Galactse) | RNA-loaded Galactose Derivative Cationic Liposome Nanoparticles |
| Galactose-modified Mercaptochitosan Quaternary Ammonium Nanoparticles (Gal-Tmc-Cys) | |
| Galactose/Chitosan-modified Nanoparticle Production | |
| Galactose Chitosan Oligosaccharide Nanoparticles | Norcantharidin-Galactose-modified Chitosan Nanoparticles (Nctd-Gc-Nps) |
| Galactose Chitosan (Gc)/ 5-Aerouracil (5-Fu) Nanoparticles | Galactose Chitosan 5-Fluorouracil Nanoparticles (Gc-5-Fu) |
| Galactosyl Chitosan Nanoparticles | |
To ensure the quality and performance of monosaccharide-based nanoparticles, several analytical techniques are employed, you can also go to our Glyconanoparticle Characterization Service Section for more comprehensive analysis services.
Zeta Potential Analysis
Assesses the surface charge of nanoparticles to ensure stability and dispersion in biological media.
Dynamic Light Scattering
Measures the size distribution of the nanoparticles.
Transmission Electron Microscopy
Provides detailed images of nanoparticle morphology.
FTIR
Helps confirm the chemical composition and functional groups on the nanoparticle surface.
UV-Vis Spectroscopy
Monitors the absorption of light to evaluate the encapsulation efficiency and release profiles of the nanoparticle.
Targeted Drug Delivery
Monosaccharide-based nanoparticles are highly effective in the development of targeted drug delivery due to their ability to be specifically designed to bind to receptors on the surfaces of particular cells.
Imaging Applications
In addition to drug delivery, monosaccharide-based nanoparticles are also valuable in the development of imaging applications. These nanoparticles can be loaded with contrast agents, making them ideal for diagnostic purposes.
Therapeutic Interventions
Monosaccharide-based nanoparticles are also pivotal in various developments of therapeutic interventions, particularly in controlled drug release and gene delivery. By modifying the surface properties of the nanoparticles with monosaccharides like galactose, they can be engineered to release therapeutic agents in a controlled manner.
Technology: GAL-PEG-GNP synthesis, Dynamic light scattering, UV-Vis spectroscopy, Transmission electron microscopy, Inductively coupled plasma mass spectrometry
Journal: Journal of Nanobiotechnology
IF: 10.6
Published: 2015
Results: This study investigates the use of galactose-functionalized gold nanoparticles (GAL-PEG-GNPs) as a radiosensitizer for enhancing the effectiveness of radiation therapy in hepatocellular carcinoma (HCC) cells. The research demonstrates that GAL-PEG-GNPs are more effectively internalized by HepG2 cells compared to bare GNPs due to their targeting of the asialoglycoprotein receptor (ASGPR) on the cell surface. Upon exposure to X-ray irradiation, GAL-PEG-GNPs significantly enhance DNA damage, cell cycle arrest, and apoptosis in HepG2 cells. The radiosensitization mechanism is attributed to the generation of free radicals, leading to increased oxidative stress and apoptosis-related protein expression.
Fig.2 Characterization of nanoparticles. (a) Shows the appearance of GNPs (left) and GAL-PEG-GNPs (right); (b) Shows the size distribution of GNPs (blue) and GAL-PEG-GNPs (red); (c) Shows absorption peak of GNPs (blue) and GAL-PEG-GNPs (red); (d) Shows the images of GNPs (left) and GAL-PEG-GNPs (right) detected by TEM. (Zhu. et al., 2015)
At CD BioGlyco, we offer monosaccharide-based nanoparticle production services that use technologies for the development of highly targeted and effective nanoparticles. Our production scale ranges from milligram to gram quantities, ensuring that we meet the needs of both small-scale research projects and large-scale pre-clinical studies. Contact us today to explore how our monosaccharide-based nanoparticle can help advance your research with tailored, high-performance products.
Reference
